How to appeal a Cigna amyloidosis (cardiac attr + al) denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna amyloidosis (cardiac attr + al) denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for amyloidosis (cardiac attr + al)
Cited policy: Cigna Amvuttra (Vutrisiran) for ATTR-CM
Adult ATTR-CM (wild-type or hereditary) confirmed per Gillmore non-invasive or biopsy. NYHA I-III. NT-proBNP elevated. eGFR >=30. Not concurrent with tafamidis, acoramidis, patisiran, or eplontersen (no stacking of TTR-directed therapies). Reauth at 9 mo with stability or improvement on 6MWD / KCCQ-OS / NT-proBNP.
How Cigna denies amyloidosis (cardiac attr + al) — and how to counter it
Where Cigna pushes back: 1) Vutrisiran experimental for ATTR-CM (outdated label review); 2) Tafamidis or acoramidis must be tried first; 3) Patisiran preferred under medical benefit; 4) RNAi reserved for hATTR-PN.
Counter-arguments that hold up: FDA approved Amvuttra (vutrisiran) for ATTR-CM on March 20, 2025 — first and only RNAi therapeutic for ATTR-CM. HELIOS-B (Fontana NEJM 2024) — 28% reduction in composite ACM + CV events HR 0.72, 36% mortality reduction over 36 mo, less decline in 6MWD + KCCQ-OS. Vutrisiran is q3mo SC vs patisiran IV q3wk — patisiran did NOT secure ATTR-CM approval (FDA Adcom 9-3 against Sep 2023 despite APOLLO-B). No step-therapy through stabilizers required per FDA label. ACC/AHA 2022 + ESC 2023 endorse disease-modifying therapy in ATTR-CM regardless of mechanism.
What Cigna typically denies for amyloidosis (cardiac attr + al)
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Vyndaqel / Vyndamax (tafamidis)
- Attruby (acoramidis)
- Amvuttra (vutrisiran) ATTR-CM
- Onpattro (patisiran)
- Wainua (eplontersen)
- D-VCd for AL
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna amyloidosis (cardiac attr + al) denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for amyloidosis (cardiac attr + al)?
For amyloidosis (cardiac attr + al), Cigna most often denies on: 1) Vutrisiran experimental for ATTR-CM (outdated label review); 2) Tafamidis or acoramidis must be tried first; 3) Patisiran preferred under medical benefit; 4) RNAi reserved for hATTR-PN. The strongest counters: FDA approved Amvuttra (vutrisiran) for ATTR-CM on March 20, 2025 — first and only RNAi therapeutic for ATTR-CM. HELIOS-B (Fontana NEJM 2024) — 28% reduction in composite ACM + CV events HR 0.72, 36% mortality reduction over 36 mo, less decline in 6MWD + KCCQ-OS. Vutrisiran is q3mo SC vs patisiran IV q3wk — patisiran did NOT secure ATTR-CM approval (FDA Adcom 9-3 against Sep 2023 despite APOLLO-B). No step-therapy through stabilizers required per FDA label. ACC/AHA 2022 + ESC 2023 endorse disease-modifying therapy in ATTR-CM regardless of mechanism.
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Amyloidosis (cardiac ATTR + AL) appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com